Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/35999| Title: | Navigating the new diabetes drugs Cardiovascular benefits and when to use. | Authors: | Szwarcbard N.;Zoungas S. | Institution: | (Szwarcbard) Clinical Research, Alfred Hospital, Monash University, Melbourne, Australia (Zoungas) School of Public Health and Preventive Medicine, Division of Metabolism, Ageing and Genomics, Monash University, Australia (Zoungas) Alfred Hospital and Monash Health, Melbourne, VIC, Australia | Issue Date: | 12-Sep-2019 | Copyright year: | 2019 | Publisher: | Medicine Today Pty Ltd (E-mail: judypasslow@medicinetoday.com.au) | Place of publication: | Australia | Publication information: | Medicine Today. 20 (8) (pp 63-66), 2019. Date of Publication: 2019. | Journal: | Medicine Today | ISSN: | 1443-430X | URI: | https://repository.monashhealth.org/monashhealthjspui/handle/1/35999 | Type: | Review | Subjects: | dapagliflozin empagliflozin ertugliflozin *glucagon like peptide 1 receptor agonist/ae [Adverse Drug Reaction] hemoglobin A1c/ec [Endogenous Compound] liraglutide metformin *sodium glucose cotransporter 2 inhibitor risk factor cardiovascular mortality gastrointestinal symptom/si [Side Effect] glucose blood level glycemic control heart infarction human hypoglycemia *non insulin dependent diabetes mellitus patient care quality of life review canagliflozin quality of life Review risk factor glucose blood level *non insulin dependent diabetes mellitus gastrointestinal symptom / side effect cardiovascular mortality hypoglycemia patient care human heart infarction glycemic control |
Type of Clinical Study or Trial: | Review article (e.g. literature review, narrative review) |
| Appears in Collections: | Articles |
Show full item record
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.